Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

Overview of attention for article published in Health Economics Review, October 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

blogs: 1 blog
twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 22 Mendeley

Summary Blogs X Facebook Dimensions citations

So far, Altmetric has seen 1 blog post.

Use of copaxone to limit the influence of spasticity associated with beta interferon use

Multiple Sclerosis Research, 19 Oct 2015

Sánchez-de la Rosa R, García-Bujalance L, Meca-Lallana J. Cost analysis of glatiramer acetate versus interferon-β for relapsing-r…